10.1210/jcem.87.3.8355 93 NauckM
Postmarketing reports have included cases of severe gastrointestinal adverse reactions , including reports of intestinal obstruction and ileus
The candidate has previously advanced through Phase IIa clinical evaluation in obese patients, as well as Phase I single ascending dose (SAD) studies in healthy volunteers and multiple ascending dose (MAD) studies in diabetic patients
It also attenuated the OXA-induced changes in some key markers [e.g., myelination (MBP), oxidative stress (nitrotyrosine), and astrocyte glial cell activation (glial fibrillary acidic protein (GFAP)] and enzymatic activity (SOD and GPx) (Abdelhamid et al., 2020)
In large obesity trials using full doses, once-weekly semaglutide and tirzepatide led to substantial average weight loss and improved metabolic markers in adults with obesity.[13] For example, the STEP 1 trial of once-weekly semaglutide in adults with overweight or obesity and the SURMOUNT-1 tirzepatide obesity trial both showed strong weight-loss effects when combined with lifestyle changes
We evaluated nine programs across pricing transparency, clinical rigor, medication breadth, coaching depth, and regulatory standing